Of 60 evaluable patients, 58 (97%) exhibited ≥1 BRCA1 or BRCA2 pathogenic tumor mutation (tBRCA1/2mut); no patients had both BRCA1 and BRCA2 mutations (Table 2, Fig. 1). This evidence concerns the gene BRCA2 and neoplasm.